Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Cancer immunotherapy, particularly chimeric antigen receptor T (CAR-T) cell therapy, has shown significant success in treating hematologic malignancies.
• The efficacy of CAR-T cell therapy in solid tumors remains a critical area of investigation.
• CAR-T cell therapy involves genetically modifying a patient's T cells to target and destroy cancer cells.

Purpose of the Study:

• To review the historical development and evolution of CAR-T cell therapy.
• To outline the structure and preparation methods of CAR-T cells.
• To summarize recent advancements in CAR-T cell therapy for diverse cancer types and discuss future prospects.

Main Methods:

• Literature review of CAR-T cell therapy history, structure, preparation, and clinical applications.
• Synthesis of current research findings on CAR-T cell therapy in various hematologic and solid tumors.
• Analysis of challenges and future directions for CAR-T cell therapy in oncology.

Main Results:

• CAR-T cell therapy has achieved remarkable clinical outcomes in CD19-positive hematologic malignancies.
• While promising results are emerging for solid tumors like glioblastoma, ovarian cancer, and cholangiocarcinoma, challenges persist.
• The review details the CAR-T cell therapy landscape, from basic principles to advanced applications.

Conclusions:

• CAR-T cell therapy represents a rapidly evolving field with significant potential in cancer treatment.
• Further research is needed to overcome challenges and optimize CAR-T cell therapy for solid tumors.
• This review provides a comprehensive overview and guidance for future CAR-T cell research and clinical application.